TOMA Biosciences and Real Time Genomics have joined forces to create a clinical grade analysis package that accurately detects DNA mutations in cancer patient samples acquired in a clinical setting.

Foster City, CA (PRWEB) July 12, 2016

TOMA Biosciencesand Real Time Genomics announce a partnership to develop novel analysis tools to process next-generation sequencing data from clinical tumor samples. Their goal is to improve somatic mutation identification to meet clinical regulatory requirements, so these tools can become an integral part of clinical testing.

Tumor profiling, using targeted next-generation sequencing of actionable cancer genes, is becoming the standard approach for selecting targeted therapies for refractory cancer patients. However, the software used by most laboratories to profile tumors originated in academic research projects, such as The Cancer Genome Atlas and the International Cancer Genome Consortium. These academic tools were designed for research protocols in